PISCATAWAY, N.J.–(BUSINESS WIRE)– March 2, 2022 Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar…Original Article
FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen
